menu search

VRPX / Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19

Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) expanded its exclusive license agreement for AnQlar with Nanomerics Ltd, providing Virpax with the worldwide rights for development and commercialization. Virpax has completed in-vitro, ex-vivo (human mucosal cells), and in-vivo (rats). Read More
Posted: Mar 15 2022, 13:56
Author Name: Benzinga
Views: 111692

VRPX News  

Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19

By Benzinga
March 15, 2022

Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) expanded its exclusive license agreement for AnQlar with Nanomerics Ltd, providing Virpax with the world more_horizontal


Search within

Pages Search Results: